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ABSTRACT
Introduction Determining whether antibiotic prescriptions 
are inappropriate requires knowledge of patients’ 
underlying conditions. In low- income and middle- income 
countries (LMICs), where misdiagnoses are frequent, this is 
challenging. Additionally, such details are often unavailable 
for prescription audits. Recent studies using standardised 
patients (SPs) offer a unique opportunity to generate 
unbiased prevalence estimates of antibiotic overuse, as 
the research design involves patients with predefined 
conditions.
Methods Secondary analyses of data from nine SP 
studies were performed to estimate the proportion of SP–
provider interactions resulting in inappropriate antibiotic 
prescribing across primary care settings in three LMICs 
(China, India and Kenya). In all studies, SPs portrayed 
conditions for which antibiotics are unnecessary (watery 
diarrhoea, presumptive tuberculosis (TB), angina and 
asthma). We conducted descriptive analyses reporting 
overall prevalence of antibiotic overprescribing by 
healthcare sector, location, provider qualification and case. 
The WHO Access–Watch–Reserve framework was used to 
categorise antibiotics based on their potential for selecting 
resistance. As richer data were available from India, we 
examined factors associated with antibiotic overuse in that 
country through hierarchical Poisson models.
Results Across health facilities, antibiotics were given 
inappropriately in 2392/4798 (49.9%, 95% CI 40.8% 
to 54.5%) interactions in India, 83/166 (50.0%, 95% CI 
42.2% to 57.8%) in Kenya and 259/899 (28.8%, 95% CI 
17.8% to 50.8%) in China. Prevalence ratios of antibiotic 
overuse in India were significantly lower in urban versus 
rural areas (adjusted prevalence ratio (aPR) 0.70, 95% 
CI 0.52 to 0.96) and higher for qualified versus non- 
qualified providers (aPR 1.55, 95% CI 1.42 to 1.70), and 
for presumptive TB cases versus other conditions (aPR 
1.19, 95% CI 1.07 to 1.33). Access antibiotics were 
predominantly used in Kenya (85%), but Watch antibiotics 
(mainly quinolones and cephalosporins) were highly 
prescribed in India (47.6%) and China (32.9%).
Conclusion Good- quality SP data indicate alarmingly 
high levels of antibiotic overprescription for key conditions 
across primary care settings in India, China and Kenya, 
with broad- spectrum agents being excessively used in 
India and China.
INTRODUCTION
Antibiotic stewardship is critical for tackling 
antimicrobial resistance (AMR), especially 
in the context of the ongoing COVID-19 
pandemic.1 In a recent systematic review on 
antibiotic prescription practices in primary 
care settings across low- income and middle- 
income countries (LMICs), we showed that 
approximately 50% of patients of any age 
seeking care for any reason received at least 
one antibiotic.2
However, determining inappropriate 
prescription in LMICs is a challenge, and 
a standardised tool for its assessment is 
currently unavailable. Inappropriate antibi-
otic prescribing can derive from a range of 
failings: (1) prescription in the absence of 
clinical indication (ie, ‘overprescription’), 
which not only produces zero benefit to the 
patient but can also be harmful (eg, drug 
toxicities or costs for patients); (2) failure 
to prescribe antibiotics when necessary 
(ie, ‘underprescription’); (3) suboptimal 
antibiotic choice with respect to aetiology 
(confirmed or presumptive), site, severity 
of infection and patient characteristics (eg, 
age, comorbidities and pregnancy status); (4) 
prescription of wrong dosage and/or dura-
tion of antibiotic treatment as compared with 
national and international guidelines.3 4
Methods used to assess inappropriateness, 
such as prescription audits, medical records 
and patient exit interviews, have multiple 
limitations.3 5 Electronic records are seldom 
available in LMICs, particularly in primary 
care, thus making accurate prescription audit 
tools difficult to implement. Also, the paucity 
and variation of clinical details that can be 
captured through medical records (paper- 
based or not), if they even exist, makes it even 
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of prescription.3 Patient exit interviews are commonly 
used alternatives but come with several major drawbacks 
that can result in poor and inaccurate estimates that are 
incomparable. Data collected in this manner are subject 
to recall bias, poor recall and limited clinical expertise 
among patients. Further, not only are clinical presenta-
tions highly heterogeneous but also the difficulty in actu-
ally determining what patients have makes comparisons 
very challenging for research.
A less biased method is the use of standardised patients 
(SPs), also known as ‘simulated’ or ‘mystery’ patients, that 
is, healthy individuals recruited from local communities 
and extensively trained to portray a standardised clinical 
condition to a healthcare provider.5 Since their clinical 
presentations are fixed by design, SPs offer an important 
opportunity to overcome the methodological limitations 
typical of other studies, thus making the assessment of 
inappropriateness of antibiotic use less biased and more 
accurate.5 Because the underlying illness is prespecified, 
the SP methodology allows accurate assessment if an anti-
biotic is inappropriately prescribed. The SP approach is 
not affected by poor recall, recall bias or the Hawthorne 
effect, which is commonly observed in patient exit 
interviews and direct observations of patient–provider 
encounters.5
Considering the aforementioned advantages, we 
performed a secondary analysis of prescription data 
from previously conducted SP studies in three LMICs 
(India, China and Kenya) with two objectives: (1) to esti-
mate the overall proportion of SP–provider interactions 
(separately for pharmacy- based and health facility- based 
studies) that resulted in prescription or dispensing of at 
least one antibiotic in the absence of clinical indication 
(ie, overprescription) and (2) to identify factors associ-
ated with antibiotic overprescribing in health facilities.
METHODS
Study design and data sources
Data on SP–provider interactions (ie, completed SP visits 
with a provider at a health facility or a pharmacy) from 
studies conducted by members of our team (India and 
Kenya) or had used SP cases developed by our team or 
obtained from publicly accessible sources (China) were 
gathered to compile a pooled dataset for secondary anal-
yses.6–15 The methods used are described in our published 
manual and toolkit on how to conduct SP studies.5
Among studies carried out in India, four involved 
primary health facilities across five sites (Delhi, Mumbai, 
Patna, three districts in the State of Madhya Pradesh, 
and Birbhum district in the State of West Bengal),6–9 
while two were performed in pharmacies located in four 
different areas (Mumbai, Patna, Delhi and Udupi district 
of Karnataka).10 11 We also examined data from a pilot 
study carried out in Nairobi (Kenya) and two studies 
completed in rural areas of China (Shaanxi, Sichuan and 
Anhui provinces), all involving only primary healthcare 
providers.12–15
Information regarding medications prescribed by 
healthcare providers were collected in these published 
SP studies but were not analysed in depth, especially with 
regard to inappropriate use. This is because, in most 
instances, the primary publications focused on overall 
quality of care, rather than the specific components of 
care.
Provider selection in original studies
Sampling approaches adopted in each primary study from 
which our data were drawn are summarised in table 1. 
For the two pharmacy- based studies, a random sample of 
pharmacies was selected from a comprehensive list of all 
those eligible obtained from relevant authorities.10 11 In 
six of the other eight studies, healthcare providers were 
Key questions
What is already known?
 ► A recent systematic review and meta- analysis showed that, across 
48 studies from 27 low- income and middle- income countries 
including China, India and Kenya, approximately half of all pa-
tients evaluated in outpatient primary care received an antibiotic 
prescription.
 ► Methods used to assess inappropriateness of antibiotic prescrip-
tion, such as prescription audits, medical records and patient exit 
interviews, have multiple limitations.
 ► Standardised patients (SPs) offer a unique opportunity to explore 
prescribing practices and accurately estimate overprescription be-
cause case presentations are fixed by design, thus allowing com-
parisons across settings and providers.
What are the new findings?
 ► In this secondary analysis of data from nine SP studies carried out 
in India, Kenya and China, we provide a more unbiased prevalence 
estimate of antibiotic overprescription for selected clinical condi-
tions (asthma, angina, watery diarrhoea, presumptive or confirmed 
tuberculosis (TB)) across a range of primary healthcare providers.
 ► About 30% of SP–provider interactions in China and 50% of those 
performed in India and Kenya resulted in inappropriate antibiotic 
prescription.
 ► Watch antibiotics (ie, broad- spectrum agents with higher potential 
for selecting resistance) were very commonly prescribed in India 
(about 50%) and China (over 32%), and some patients (0.8%) even 
received last- resort antibiotics belonging to the ‘Reserve’ group.
 ► In India, the average prevalence of antibiotic prescribing was 30% 
lower in urban versus rural areas, 55% higher among qualified 
providers compared with non- qualified ones and 19% higher for 
patients presenting with presumptive TB versus other conditions.
What do the new findings imply?
 ► Our findings indicate alarming levels of antibiotic overprescription 
for conditions that are frequently encountered in primary care, po-
tentially leading to toxic effects and diagnostic delays.
 ► The choice of antibiotics given to patients is concerning, as several 
agents with high potential for resistance selection are often inap-
propriately prescribed.
 ► The SP methodology could prove useful to further investigate anti-
biotic prescribing practices and its underlying determinants, using 
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randomly sampled after performing a census or street- by- 
street mapping in the study areas.7–9 13–15 A convenience 
sample of practitioners was selected in two pilot studies 
respectively performed in Delhi and Nairobi.6 12 A waiver 
of provider consent was obtained in four out of nine 
studies, all carried out in India, two of which involved 
pharmacies.7 9–11 In all the others, verbal or written 
informed consent was sought at least 6 weeks prior to the 
commencement of SP–provider interactions in order to 
reduce the risk of SP detection. Yet, participation rates 
were very high (85%–100%) among eligible health 
practitioners, and non- participation was usually due to 
logistical issues on the day of the visits rather than active 
refusal to be involved in the project. Hence, it is reason-
able to expect negligible differences between participants 
and non- participants, making non- response bias a minor 
concern. In all studies, SPs were randomly assigned to 
providers, and completion rates of SP–provider interac-
tions were always very high.
Tracer conditions
Tracer conditions (ie, SP case presentations) were 
defined similarly across SP studies, thus allowing compar-
isons across settings. Cases ranged from presumptive or 
confirmed tuberculosis (TB) (which requires specific 
anti- TB treatment as per WHO recommendations) to 
self- limiting infections, such as watery diarrhoea or upper 
respiratory tract illness (which only need support treat-
ment, eg, rehydration therapy for diarrhoea), to non- 
communicable diseases like asthma or chest pain indica-
tive of angina (these should be referred to a higher level 
of care). Importantly, none of such conditions requires 
antibiotics, which means that any antibiotic prescribed to 
SPs is deemed inappropriate by indication (ie, overpre-
scription).
Outcome assessment
Raw data from original studies were harmonised and 
recoded as needed. We used the available information 
on medications that were prescribed or dispensed during 
each SP–provider interaction to categorise individual 
drugs. Antibacterial agents were further classified using 
both the ATC (Anatomical–Therapeutic–Chemical) 
Index and the WHO Access–Watch–Reserve (AWaRe) 
framework.16 17 Fixed- dose combinations (FDCs) of anti-
biotics (eg, ciprofloxacin/ornidazole) were classified as 
‘discouraged’ antibiotics as per WHO recommendations.
The primary outcome measure was expressed as the 
proportion of SP–provider interactions that resulted 
in antibiotic prescription or dispensing. Secondary 
outcomes were proportions of specific groups of antibi-
otics that were prescribed or dispensed both overall and 
across strata of key variables of interest. These propor-
tions provide a direct measure of antibiotic overuse.
Statistical analyses
For studies carried out in health facilities, we conducted 
country- level descriptive analyses and reported the crude 
proportion of SP–provider interactions that resulted 
in antibiotic prescription or dispensing. The overall 
proportion of prescribed or dispensed antibiotics, along 
with ATC- class and AWaRe group- specific proportions, 
was calculated across strata defined by key variables of 
interest, such as healthcare sector (public/private), 
facility location (urban/rural), provider qualification 
(qualified/non- qualified, defined based on whether they 
had at least a bachelor’s degree in medicine) and tracer 
conditions. For all prevalence proportions, we computed 
95% CIs using bootstrapping in order to account for clus-
tering at the study level.18
In order to examine the factors associated with anti-
biotic prescribing in health facilities in India, we fit a 
hierarchical Poisson regression model that allows direct 
estimation of adjusted prevalence ratios (aPRs) even if the 
outcome is common as in this case. Our model included 
a random intercept for studies and dummy variables for 
facility location, healthcare sector, provider qualification 
and tracer conditions as predictors.19 As we anticipated a 
fair amount of between- study heterogeneity, we decided 
to opt for a mixed model that could better account for 
it as compared with including the study or study site as a 
covariate. Among tracer conditions, only angina, asthma 
and presumptive TB could be included in order to avoid 
sparse data problems (ie, violations of the positivity 
assumption). The effect of all predictors was expected to 
be similar across studies, and therefore only fixed slopes 
were considered. These analyses were restricted to India 
because we had diverse and more data. We also consid-
ered alternative models and examined the pros and cons 
of each. A full description of our analyses is provided in 
online supplementary file 1.
Data from pharmacies were not pooled because contexts 
and tracer conditions were highly heterogeneous in the 
two available studies. Therefore, we only calculated prev-
alence proportions and 95% CIs of dispensed antibiotics, 
both overall and in stratified analyses.
All analyses were performed using Stata 16.
Patient and public involvement
It was not possible to involve patients or the public in the 
design, conduct, reporting or dissemination plans of our 
research because this is a secondary analysis of previously 
conducted studies.
RESULTS
The main features of SP studies that were included in 
our analyses are summarised in table 1. A total of 4798 
SP–provider interactions were completed in health 
facilities across urban and rural India, predominantly 
in the private sector. Both private and public health-
care providers were involved in the pilot study carried 
out in Nairobi (166 interactions), whereas studies from 
rural China only targeted the public sector (899 inter-


















ealth: first published as 10.1136/bm






Sulis G, et al. BMJ Global Health 2020;5:e003393. doi:10.1136/bmjgh-2020-003393 5
BMJ Global Health
present summary statistics and then report results from 
our models.
Antibiotic overuse across settings
In India, 2392 of 4798 (49.9%, 95% CI 40.8% to 54.5%) 
SP–provider interactions resulted in at least one anti-
biotic prescription (table 2). Similar proportions were 
observed in Nairobi (83 of 166; 50.0%, 95% CI 42.2% to 
57.8%), while a lower percentage was found in the China 
studies (259 of 899; 28.8%, 95% CI 17.8% to 50.8%). 
However, in the latter case, the CI was substantially wide, 
reflecting the considerable between- study variance due 
to differences in tracer conditions evaluated.
In most instances, only one antibiotic was given 
during an individual SP–provider interaction; less than 
5% of interactions across all settings resulted in two or 
more antibiotics prescriptions. Crude analyses of data 
from India indicate that antibiotic overprescription was 
more common among healthcare providers in urban 
areas, among those working in the private sector and 
among qualified professionals. Furthermore, antibiotics 
were largely overprescribed to patients presenting with 
a diverse range of clinical conditions in all countries 
(figure 1). In India, the percentage of subjects receiving 
antibiotics was close to 50% for most case types, with a 
peak of 59.4% (95% CI 50.5% to 75.0%) among child 
diarrhoea cases. However, for angina cases, it was 19.2% 
(95% CI 16.8% to 21.1%). About half of the visits for 
presumptive TB in China received antibiotics inappro-
priately, as opposed to 9.2% (95% CI 5.9% to 12.4%) of 
visits for suspicious angina and 27.4% (95% CI 21.8% to 
32.5%) for child diarrhoea. Case- specific estimates from 
Nairobi are highly imprecise due to the small sample size.
Type of antibiotics used
Across studies performed in India, 2768 antibiotics were 
given to 2392 patients. The top 10 most prescribed antibi-
otics across SP–provider interactions in India were azith-
romycin (381, 13.8%), amoxicillin+beta- lactamase inhib-
itor (344, 12.4%), amoxicillin (264, 9.5%), levofloxacin 
(202, 7.3%), cefixime (198, 7.2%), ofloxacin (165, 6.0%), 
ofloxacin+ornidazole (150, 5.4%), norfloxacin+tinida-
zole (136, 4.9%), ciprofloxacin (102, 3.7%) and cefpo-
doxime (88, 3.2%). Broad- spectrum agents with higher 
potential for selecting resistance (Watch antibiotics) were 
disproportionately represented (47.6%, 95% CI 26.8% to 
54.0%), and even more so in urban areas (54.9%, 95% CI 
54.9% to 55.4%) (table 3). This reflects the heavy use of 
quinolones, cephalosporins and macrolides that respec-
tively accounted for 18.8% (95% CI 16.6% to 24.2%), 
13.0% (95% CI 8.2% to 14.6%) and 15.4% (95% CI 4.1% 
to 19.3%) of all antibiotics prescribed in India. Nearly 
80% of Watch antibiotics were given to SPs portraying 
a TB case (1086/1362). Three different last- resort or 
‘Reserve’ antibiotics (colistin, linezolid and faropenem) 
were prescribed in a total of 23 SP–provider interactions 
in India, mainly for child diarrhoea (14/23).
Discouraged antibiotics, that is, FDCs other than anti-
mycobacterial drugs (such as norfloxacin+tinidazole or 
ofloxacin+ornidazole) accounted for 12.1%, of which all 
but one were given for child diarrhoea. Anti- TB medi-
cations represented 8.3% of antibiotics in India; almost 
all of them were given by healthcare providers in urban 
areas; and none could be considered appropriate based 
on the expected correct management of such cases.
About one- quarter of drugs prescribed in studies from 
China could not be categorised based on the AWaRe 
framework because only the drug class was reported. 
These were mainly cephalosporins, most likely second 
or higher generation, and therefore the overall propor-
tion of Watch- group antibiotics is expected to be greater 
than 32.9% (table 3). Undefined cephalosporins were 
by far the most prescribed antibiotics in China (76/301, 
25.2%), followed by gentamicin (45/301, 15.0%), amox-
icillin (37/301, 12.3%), erythromycin (26/301, 8.6%) 
and levofloxacin (18/301, 6.0%).
Subgroup analyses of antibiotic prescription patterns 
among SP–provider interactions that took place in 
Nairobi were limited by the small sample size. However, 
85.4% (76/89) of all antibiotics prescribed were first- line 
and narrow- spectrum agents from the ‘Access’ group, 
while the remaining belonged to the ‘Watch’ group.
Factors associated with antibiotic overuse in India
Prevalence ratios of antibiotic overuse and their 95% 
CIs estimated through mixed- effects Poisson regression 
analysis are reported in figure 2. The adjusted preva-
lence of antibiotic prescribing was lower in urban versus 
rural areas (aPR=0.70; 95% CI: 0.52 to 0.96), for subjects 
presenting with suspicious angina (aPR=0.33; 95% CI: 
0.27 to 0.40), and asthma (aPR=0.77; 95% CI: 0.66 to 
0.89). Patients with presumptive TB were more likely to 
receive inappropriate antibiotics (aPR=1.19; 95% CI: 1.07 
to 1.33) as compared with individuals with other clinical 
conditions. Qualified practitioners were more likely to 
prescribe antibiotics than non- qualified ones (aPR 1.55; 
95% CI: 1.42 to 1.70).
The hierarchical Poisson model did not show any signif-
icant difference between public and private providers, 
but this is in contrast with what emerged from alternative 
models as described in online supplementary file 1.
Antibiotic dispensing in pharmacies
Our secondary analysis of data from two pharmacy- 
based SP studies showed that over- the- counter antibiotic 
dispensing is also a common problem in various parts of 
India (table 4).
In Udupi district (Karnataka state) the proportion of 
SP—pharmacist interactions that resulted in antibiotic 
dispensing was 3.6% (95% CI: 2.6 to 4.6), with a similar 
pattern in both urban and rural areas. In contrast, at 
least one antibiotic was dispensed in 319/1,200 inter-
actions performed across Delhi, Mumbai and Patna, 
corresponding to 26.6% (95% CI: 24.2 to 29.2) of the 
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studies is not possible owing to the very different contexts 
involved and particularly to the different types of cases 
that were examined. As observed in studies from health-
care facilities, subjects presenting to pharmacies with 
symptoms suggestive of TB were generally more likely to 
receive an antibiotic as compared with other conditions.
The average proportion of Watch- antibiotics (predom-
inantly quinolones and cephalosporins) dispensed across 
the three cities was 49.4% (95% CI: 43.9 to 54.4), ranging 
from 24.0% (95% CI: 15.0 to 32.0) in Mumbai to 60.9% 
(95% CI: 55.1 to 67.1) in Patna. A deeper evaluation of 
antibiotic dispensing in Udupi district is limited by the 
small sample size. Only 55 antibiotics were dispensed 
across 1522 interactions, thus making subgroup anal-
yses less meaningful. Yet, it is worth highlighting that 
nearly half of these antibiotics were discouraged FDCs 
of two antibiotics, whereas the remaining were almost 
equally distributed among Access- and Watch- groups. 
More details regarding the types of antibiotics dispensed 
across pharmacies in both studies are presented in online 
supplementary file 2.
DISCUSSION
Our analysis of past SP studies involving 4798 SP–provider 
interactions in India showed that healthcare providers 
in primary care settings prescribed antibiotics to about 
half (49.9%) of patients presenting with clinical condi-
tions that do not require antibiotics. Antibiotic overpre-
scribing was found to be similar (50% of SP–provider 
interactions) in a small SP study carried out in Nairobi, 
Kenya. Pooled data from two studies conducted in China 
showed lower levels of antibiotic overuse (28.8%), but it 
should be noted that percentages differed substantially 
across individual studies, likely reflecting the different 
type of cases being involved. In fact, SP–provider interac-
tions involving presumptive TB cases were more likely to 
result in antibiotic prescription as compared with other 
clinical conditions. Among the two pharmacy- based SP 
studies done in India,10 11 the proportion of antibiotic 
dispensing was 26.6% and 3.6%, respectively.
Although our focus was on LMICs, the overuse of anti-
biotics is not confined to LMICs. Large population- based 
cohort data have shown that antibiotic overuse in ambu-
latory settings across the United States was 30% among 
children and 17% among adults with certain respiratory 
tract illnesses for which antibiotics are not indicated 
(eg, asthma, allergies, acute bronchitis or bronchiol-
itis).20 An analysis of antibiotic prescription practices 
based on administrative data from Ontario, Canada, 
recently reported an overall rate of unnecessary antibi-
otic prescribing in primary care of 15.4%, though much 
higher percentages were observed for some respiratory 
conditions such as acute bronchitis (52.6%).21 However, 
a direct comparison with higher income countries cannot 
be done due to differences in study methodologies and 
local epidemiology.
Nearly 50% of all antibiotics prescribed in the context 
of India SP studies belonged to the ‘Watch’ list, with a 
peak of 80% among patients presenting with symptoms 
suggestive of TB, which is consistent with national antibi-
otic sales.22 Watch- antibiotics accounted for almost 33% 
of all antibiotics across China SP studies, but this is likely 
underestimated because nearly one quarter of all antibi-
otics could not be classified due to insufficient informa-
tion. Of note, we observed a large use of cephalosporins 
(presumably second or third generation ones), which is 
in line with previous findings from drug sales analyses 
and prescription audits conducted in various parts of 
China.2 23 24 In contrast, the small SP study conducted 
in Nairobi revealed that over 85% of prescribed antibi-
otics were from the ‘Access’ group, and half of these were 
either trimethoprim/sulfamethoxazole or amoxicillin. 
Figure 1 Crude percentage of SP—provider interactions resulting in antibiotic prescription/dispensing, by country and 
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This is in line with that observed in another SP study 
carried out in urban public primary healthcare facilities 
in South Africa, where 10/119 (8.4%) interactions for 
presumptive TB resulted in antibiotic prescriptions, all of 
which belonged to the access group.25 As with the Nairobi 
study, however, the small sample size does not allow to 
draw meaningful conclusions on antibiotic prescribing 
patterns in the area.
Discouraged FDCs of antibiotics were commonly given 
in India but not in other settings, accounting for 10.4% of 
the total. FDCs were finally banned in India in September 
2018, thus leaving hope for a change in the near future.
Figure 2 Factors associated with antibiotic prescribing/dispensing in health facilities in India. Covariate- adjusted prevalence 
ratios and their 95% CIs estimated from a hierarchical Poisson model are reported. SP, standardised patient; TB, tuberculosis.





Mumbai, Delhi and Patna
(n=1200)
n/N Proportion (95% CI) n/N Proportion (95% CI)
Number of antibiotics
  1 55/1522 3.6 (2.6 to 4.6) 294/1,00 24.5 (22.2 to 27.0)
  2 0 0 25/1200 2.1 (1.3 to 2.9)
Pharmacy location
  Urban 25/744 3.3 (2.2 to 4.7) 319/1200 26.6 (24.2 to 29.2)
  Rural 30/778 3.9 (2.7 to 5.2) – –
Clinical presentation
  Adult with URI 11/250 4.4 (2.0 to 7.2) – –
  Adult with diarrhoea 12/259 4.6 (2.3 to 7.1) – –
  Adult with fever (malaria suspect) 10/252 4.0 (1.6 to 6.3) – –
  Child with URI 0/252 0 – –
  Child with diarrhoea 20/250 8.0 (4.8 to 11.2) – –
  Child with fever (malaria suspect) 2/259 0.8 (0.4 to 1.9) – –
  Adult with presumptive TB – – 221/599 36.9 (33.1 to 40.7)
  Adult with confirmed TB – – 98/601 16.3 (13.5 to 19.3)
Patient referred to health provider
  Yes 15/710 2.1 (1.1; 3.1) 41/497 8.2 (5.8; 10.9)
  No 40/812 4.9 (3.6; 6.4) 278/703 39.5 (36.1; 43.2)
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Alarmingly, we observed the use of some ‘Reserve’ anti-
biotics in primary care settings. In India, oral colistin was 
prescribed for paediatric diarrhoea, and faropenem was 
given to one patient with presumptive TB. This is very 
concerning as parenteral colistin is the last resort drug 
for treatment of extremely drug- resistant Gram- negative 
infections,26 and using the oral formulation could drive 
resistance in the community. Similarly, faropenem is an 
oral penem antibiotic which has been shown to cause 
cross- resistance to intravenous carbapenems.27 In China 
SP studies, one presumptive TB case received aztreonam, 
indicated for treatment of serious infections due to drug- 
resistant Gram- negative bacteria.
According to our findings from India, antibiotic overuse 
was particularly common in rural areas, among qualified 
providers and for patients presenting with presumptive 
TB. Besides leading to potentially dangerous diagnostic 
delays,28 29 the unnecessary use of antibiotics causes 
harms to the patient in terms of drug- associated adverse 
events and increased out- of- pocket costs.
While normative boundaries may partly explain why 
qualified providers prescribed more antibiotics than 
non- qualified ones as observed in our analyses for 
India, the widespread overuse of antibiotics suggests 
that important training gaps likely exist. However, 
prescribing behaviours among healthcare providers 
also depend on a number of other factors, including 
financial incentives from pharmaceutical companies, 
patient expectations and requests, or just old habits that 
are hard to die.8 30 31
The biggest strength of our study lies in the nature 
and quality of the data used to investigate the extent and 
patterns of antibiotic overprescribing. Although previous 
research had already highlighted that Watch group anti-
biotics are highly prescribed across India and China, 
such studies could not provide a clear picture of inap-
propriate antibiotic use owing to the limited amount of 
clinical information available from prescription audits 
and evaluations of drug sales data.32–34 Among the main 
advantages of using SPs to evaluate prescription practices 
is the fact that tracer conditions are standardised.5 In all 
studies included in our analyses, such conditions were 
very common illnesses that are frequently encountered 
in primary care and that require a well- defined diagnostic 
and therapeutic management that does not involve anti-
biotic use.
Furthermore, representative samples of healthcare 
providers from public and/or private sectors were 
selected in all SP studies conducted in India, with the 
only exception of one relatively small pilot study in 
Delhi. In this pooled dataset, private practitioners were 
much more represented than public providers, but we 
lacked statistical power to make appropriate compari-
sons between the two groups. Yet, this distribution well 
reflects the fact that about 75% of outpatient visits in 
India take place in the private sector, with nearly 70% of 
primary care in the country being delivered by informal 
providers.35 36
Of note, available data originated from a range of 
geographical areas with different sociocultural and 
economic profiles and could be generalisable to similar 
contexts in India. For all these reasons, the representa-
tiveness of our findings is very good, and selection bias is 
likely negligible due to the robust mapping and sampling 
approach used across all SP studies.
There are limitations in our study. First, the SP study data 
from China and Kenya were limited and lacked general-
isability. Second, our analyses were restricted to overpre-
scription and to a limited number of clinical scenarios. 
Third, we could not investigate other important forms 
of inappropriate antibiotic use, such as the choice of the 
incorrect drug and dosage to treat a given infection. This 
is an intrinsic limitation that arises from the type of tracer 
conditions used across SP studies so far. Although the SP 
methodology was initially implemented to assess overall 
quality of care in LMICs and to evaluate educational/
behavioural programmes in high- income countries, this 
approach is being increasingly adopted to gain insight 
into medication use, and especially drug dispensing prac-
tices among pharmacists. Data recording systems in SP 
studies are therefore improving in order to facilitate the 
collection of key details regarding medications that were 
harder to capture from studies whose main objective was 
not related to drug use.
In conclusion, the prevalence of antibiotic overpre-
scribing estimated from SP studies ranged from 29% 
in China to 50% in India and Kenya, and Watch anti-
biotics accounted for a large proportion of antibiotics 
prescribed in both India and China. Combining the SP 
methodology with new tracer conditions would allow 
overcoming many of the typical limitations of most 
studies aimed at evaluating inappropriate antibiotic use 
in greater detail. SPs represent a unique opportunity to 
further explore prescription practices among healthcare 
providers, including the management of common infec-
tious diseases, such as pneumonia or urinary tract infec-
tions, that contribute substantially to the overall antibiotic 
use in primary care. Future studies also need to focus on 
untangling the channels for antibiotic overprescription 
and better understand the determinants of such practice 
among public and private healthcare providers in various 
contexts.
The extent of antibiotic overuse in primary care across 
LMICs is a serious concern and requires targeted anti-
microbial stewardship interventions aimed at improving 
rational and locally adapted prescribing practices. An 
active involvement of private providers in all such inter-
ventions would be essential to ensure uptake, particularly 
in countries where the private sector plays a major role in 
healthcare. Greater efforts are also necessary to develop 
and scale up accurate point- of- care tests that could guide 
therapeutic choices where resources are scarce. Addi-
tional research is also required to evaluate whether anti-
biotic use (especially use of drugs such as azithromycin 
and hydroxychloroquine) will dramatically increase as a 
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have already been raised about the implications for 
AMR.37
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